(Q36679733)

15 August 2017

1 reference

title

Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer (English)

1 reference

15 August 2017

1 reference

4

David Cella

1 reference

15 August 2017

3

Ignace Vergote

1 reference

15 August 2017

Richard T Penson

1

1 reference

PubMed ID

17161164

15 August 2017

Lari B Wenzel

series ordinal

2

1 reference

15 August 2017

1 November 2006

1 reference

International Journal of Gynecology and Obstetrics

15 August 2017

1 reference

15 August 2017

95 Suppl 1

1 reference

15 August 2017

S247-57

1 reference

Unresolved issues in the chemotherapeutic management of gynecologic malignancies

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

What do global quality-of-life questions really measure? Insights from Hobday et al and the "do something" rule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Psychological well being and quality of life in ovarian cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of Life of Women with Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality-of-life assessment in cancer treatment protocols: research issues in protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of life in cancer patients--an hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

A nerve-sparing radical hysterectomy: guidelines and feasibility in Western patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Defining and measuring reproductive concerns of female cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Interval debulking surgery in advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Management of treatment-related toxicity in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologo

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Informed consent, cancer, and truth in prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Changing patient perceptions of the side effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality-of-Life Issues in Patients With Ovarian Cancer and Their Caregivers:

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of life: gynaecological cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Sexual implications of gynecologic cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Sexual functioning morbidity among cancer survivors. Current status and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

The cancer patient and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Reliability and validity of the functional assessment of cancer therapy-ovarian.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Can you measure a sunbeam with a ruler?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Beyond the development of quality-of-life instruments: where do we go from here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Science, language, intuition, and the many meanings of quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Type II radical hysterectomy: evaluating its role in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7292%2806%2960040-4

10.1016/S0020-7292(06)60040-4

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference